New approaches for modelling cancer mechanisms in the mouse

Journal of Pathology

Volumn 205, Issue 2, 2005, Pages 181-193

  Maddison, Kathryn ^a   Clarke, Alan R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Conditional alleles; Ki Ras; Mouse models of cancer; Myc; p53; Rb

Indexed keywords

CRE RECOMBINASE; K RAS PROTEIN; MYC PROTEIN; PROTEIN P53; TETRACYCLINE; TUMOR SUPPRESSOR PROTEIN;

ACCURACY; ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RESEARCH; CARCINOGENESIS; DEVELOPMENTAL STAGE; DISEASE ACTIVITY; DISEASE MODEL; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; GENETIC MANIPULATION; IN VIVO STUDY; KNOCKOUT GENE; LETHALITY; LIFE CYCLE; LOXP SITE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TISSUE SPECIFICITY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENES;

EID: 13644266446     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1698     Document Type: Review

References (126)

1. Rangarajan A, Weinberg RA. Comparative biology of mouse versus human cells: modelling human cancer in mice. Nature Rev Cancer 2003; 3: 952-959.
2. DePinho RE. The age of cancer. Nature 2000; 408: 248-254.
3. Blasco MA, Lee HW, Hande MP, et al. Telomere shortening and tumour formation by mouse cells lacking telomerase RNA. Cell 1997; 91: 25-34.
4. Adams JM, Harris AW, Pinkert CA, et al. The c-Myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
5. McCleod KF, Jacks T. Insights into cancer from transgenic mouse models. J Pathol 1999; 187: 43-60.
6. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-2262.
7. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation on the mouse. Nature 1992; 359: 259-300.
8. Harrison DJ, Hooper ML, Armstrong JF, Clarke AR. Effects of heterozygosity for the Rb-1t19 neo allele in the mouse. Oncogene 1995; 10: 1615-1620.
9. Dyer MA, Cepko CL. Regulating proliferation during retinal development. Nature Rev Neurosci 2001; 2: 333-342.
10. Kip2 regulate proliferation in distinct retinal progenitor cell populations. J Neurosci 2001; 21: 4259-4271.
11. Robanus-Maandag E, Dekker M, Van Der Walk M, et al. p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 1998; 12: 1599-1609.
12. Clarke AR, Maandberg ER, Von Roon M, et al. Requirement for a functional Rb1 gene in murine development. Nature 1992; 359: 328-330.
13. Lee EY, Chang CY, Hu N, et al. Mice deficient for Rb are non-viable and show defects in neurogenesis and haematopoiesis. Nature 1992; 359: 228-294.
14. Palmiter RD, Brinster RL. Germ-line transformation of mice. Annu Rev Genet 1986; 20: 465-499.
15. Dorer DR. Do transgene arrays form heterochromatin in vertebrates? Transgenic Res 1997; 6: 3-10.
16. Politi K, Kljuic A, Szabolcs M, Fisher P, Ludwig T, Efstratiadis A. Designer tumours in mice. Oncogene 2004; 23: 1558-1565.
17. Hanhan D. Heritable formation of pancreatic B-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40. Nature 1985; 315: 115-122.
18. Shibata H, Toyama K, Shioya H, et al. Rapid colorectal adenoma. formation initiated by conditional targeting of the Apc gene. Science 1997; 278: 120-123.
19. Jonkers J, Berns A. Conditional mouse models of cancer. Nature Rev Cancer 2002; 2: 251-265.
20. Baranda CS, Dymecki SM. Talking about a revolution : the impact of site-specific recombinases on genetic analyses in mice. Dev Cell 2004; 6: 7-28.
21. Stenberg N, Hamilton D. Bacteriophage P1 site-specific recombination. I. Recombination between LoxP sites. J Mol Biol 1981; 150: 467-486.
22. Kuhn R, Torres RM. Cre/loxP recombination system and gene targeting. Methods Mol Biol 2002; 180: 175-204.
23. Hoess R, Ziese M, Stenberg N. P1 site-specific recombination : nucleotide sequence of the recombining sites. PNAS 1982; 79 3398-3402.
24. O'Gorman S, Fox DT, Wahl GM. Recombinase mediated gene activation and site-specific integration in mammalian cells. Science 1991; 251: 1351-1355.
25. Schmidt EE, Taylor DS, Prigge JR, Barnett S, Capecchi M. Illegitimate Cre-dependent chromosome re-arrangements in transgenic mouse spermatids. PNAS 2000; 97: 13 702-13 707.
26. Tyagarajan B, Guimaraes MJ, Calos MP. Mammalian genomes contain active recombinase recognition sites. Gene 2000; 244: 47-54.
27. Silver DP, Livingston DM. Self-excising retroviral vectors encoding the Cre recombinase overcome Cre-mediated cellular toxicity. Mol Cell 2001; 8: 233-243.
28. Metzger D, Chambon P. Site- and time-specific gene targeting in the mouse. Mol Methods 2001; 24: 71-80.
29. Prost S, Sheahan S, Rannie D, Harrison DJ. Adenovirus-mediated Cre deletion of floxed sequences in primary mouse cells is an efficient alternative for studies of gene deletion. Nucleic Acids Res 2001; 29: E80.
30. Wagner KU, Wall RJ, St-Onge L, et al. Cre-mediated gene deletion in the mammary gland. Nucleic Acids Res 1997; 25: 4323-4330.
31. Selbert S, Bentley DJ, Melton DW, et al. Efficient BLG-Cre mediated gene deletion in the mammary gland. Transgenic Res 1998; 5: 387-396.
32. Ireland H, Kemp R, Houghton C, et al. Inducible Cre-mediated control of gene expression in the murine gastrointestinal tract: effect of loss of β-catenin. Gastroenterology 2004; 126 1236-1246.
33. Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. PNAS 1992; 89: 5547-5551.
34. Baron U, Bujard H. Tet-repressor-based system for regulated gene expression in mammalian cells: principles and advances. Methods Enzymol 2000; 327: 401-421.
35. Zhou Z, Zheng T, Lee CG, Homer RJ, Elias J. Tetracycline-controlled transcriptional regulation systems: advances and applications in transgenic animal modelling. Cell Dev Biol 2002; 13: 121-128.
36. No D, Yao TP, Evans RM. Ecdysone-inducible gene expression in mammalian cells and transgenic mice. PNAS 1996; 93: 3346-3351.
37. Ngan ES, Schillinger K, DeMayo F, Tsai SY. The mifepristone-inducible gene regulatory system in mouse models of disease and therapy. Semin Cell Dev Biol 2002; 13: 143-149.
38. Cronin CC, Gluba W, Scrable H. The Lac operator-repressor system is functional in the mouse. Genes Dev 2001; 15: 1506-1517.
39. Wang XJ, Liefer KM, Tsai S, O'Malley BW, Roop DR. Development of gene-switch transgenic mice that inducibly express transforming growth factor β in the epidermis. PNAS 1999; 96: 8483-8488.
40. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
41. Park MT, Lee SJJ. Cell cycle and cancer. Biochem Mol Biol 2003; 36: 60-65.
42. Lesli NR, Downes P. PTEN function: how normal cells control it and tumour cells lose it. Biochem J 2004; 382: 1-11.
43. Wu X, Huang J, Powell WC, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech Dev 2001; 101: 61-69.
44. Lesche R, Groszner M, Gao J, et al. Cre/LoxP-mediated inactivation of the murine Pten tumour suppressor gene. Genesis 2002; 32: 148-149.
45. You MJ, Fukabori Y, McBride G, et al. Genetic analysis of Pten and INK4a/Arf in the suppression of tumourigenesis in mice. PNAS 2002; 99: 1455-1460.
46. Rane SG, Dubus P, Mettus RV, et al. Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in B-cell hyperplasia. Nature Genet 1999; 22: 44-52.
47. Tsutsui T, Hesabi B, Moons DS, Pandolfi PP, Hansel KS, Koff A, et al. Targeted disruption of Cdk4 delays cell cycle entry with enhanced P27Kip1 activity. Mol Cell Biol 1999; 19: 7011-7019.
48. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004; 118: 493-504.
49. Marinkovic D, Marinkovic T, Mahr B, et al. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004; 110: 336-342.
50. Pelengaris S, Littlewood T, Khan M, Elia G, Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell 1999; 3: 565-577.
51. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002; 297: 102-104.
52. Malumbres M, Barbacid M. RAS oncogenes : the first 30 years. Nature Rev Cancer 2002; 3: 7-13.
53. Koera K, Nakamura K, Nakao K, et al. K-ras is essential for the development of the mouse embryo. Oncogene 1997; 15: 1151-1159.
54. Johnson L, Greenbaum D, Cichowski K, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev 1997; 11: 2468-2481.
55. Umanoff H, Edelmann W, Pellicer A, et al. The murine N-Ras gene is not essential for growth and development. PNAS 1995; 92: 1709-1713.
56. Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol 2001; 21: 1444-1452.
57. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early-onset lung cancer in mice. Nature 2001; 410: 1111-1116.
58. Guerra C, Mijimolle N, Dhawahir A, Dubus P, Barrada M, Serrano M, et al. Tumour induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 2003; 4: 111-120.
59. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
60. Meuwissen R, Linn SC, van der Valk M, Mooi WJ, Berns A. A mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 2001; 20: 6551-6558.
61. Serrano M, Blasco MA. Putting the stress on senescence. Curr Opin Cell Biol 2001; 13(6): 748-753.
62. Wong AK, Chin L. An inducible melanoma model implicates a role for RAS in tumor maintenance and angiogenesis. Cancer Metastasis Rev 2000; 19: 121-129.
63. Zhang J, Schweers B, Dyer MA. The first knockout mouse model of retinoblastoma. Cell Cycle 2004; 3: 952-959.
64. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. Trends Pharmacol Sci 2004; 25: 177-181.
65. Sansom OJ, Clarke AR. P53 null mice: damaging the hypothesis? Mutation Res 2000; 452(2): 149-162.
66. Lowe SW, Schmitt EM, Smith SW, et al. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849.
67. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
68. Purdie CA, Harrison DJ, Peter A, et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994; 9: 611-619.
69. Clarke AR, Hollstein M. Mouse models with modified p53 sequences to study cancer and ageing. Cell Death Differ 2003; 10 443-450.
70. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today 1997; 3: 390-395.
71. Donehower L, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
72. Lozano G, Zambetti GP. What have animal models taught us about the p53 pathway? J Pathol 2005; 205: 206-220.
73. Hergenhahn M, Luo JL, Hollstein M. p53 designer genes for the modern mouse. Cell Cycle 2004; 3: 738-741.
74. Liu Z, Hergenhahn M, Schmeiser HH, Wogan GN, Hong A, Hollstein M. Human tumour p53 mutations are selected for in mouse embryonic fibroblasts harbouring a humanized p53 gene. PNAS 2004; 101: 2963-2968.
75. Liu G, Parant JM, Lang G, et al. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumourigenesis in Trp53 mutant mice. Nature Genet 2004; 36: 63-68.
76. Venkatachalam S, Shi YP, Jones SN, et al. Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J 1998; 17: 4657-4667.
77. Jiminez GS, Mister M, Stommel JM, et al. A Transactivation-deficient Trp53 mouse model provides insights into Trp53 regulation and function. Nature Genet 2000; 26: 37-47.
78. Zabkiewicz J, Clarke AR. DNA damage induced apoptosis: insights from the mouse. BBA Rev Cancer (in press).
79. Moore L, Venkatchalam S, Vogel H, et al. Cooperativity of p19ARF, Mdm2 and p53 in murine tumourigenesis. Oncogene 2003; 23: 7831-7837.
80. Kamijo T, Weber JD, Zambetti G, Zindy F, Roussel MF, Sherr CJ. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc Natl Acad Sci U S A 1998; 95: 8292-8297.
81. Zhang Y, Xiong Y, Yarbrough WG. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998; 92: 725-734.
82. Palmero I, Pantoja C, Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 1998; 395: 125-126.
83. Zindy F, Eischen CM, Randle DH, et al. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev 1998; 12 2434-2442.
84. Bergers G, Benjamin LE. Tumourigenesis and the angiogenic switch. Nature Rev Cancer 2003; 3: 401-410.
85. Volpert OV, Alani RM. Wiring the angiogenic switch: Ras, Myc and thrombospondin-1. Cancer Cell 2003; 3: 199-200.
86. Lawler J. Thrombospondin-1 as an endogenous inhibitor of angiogenesis and tumor growth. Cell Mol Med 2002; 6: 1-12.
87. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Exp Cell Res 1965; 37: 614-636.
88. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalisation of normal human diploid fibroblasts. Mol Cell Biol 1989; 9: 3088-3092.
89. Meeker AK, Hicks JL, Iacobuzio-Donahue CA, et al. Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Cancer Res 2004; 10: 3317-3326.
90. Blackburn EH. Structure and function of telomeres. Nature 1991; 350: 569-572.
91. Shay JW, Wright WE, Werbin H. Defining the molecular mechanisms of human cell immortalisation. Biochim Biophys Acta 1991; 1072: 1-7.
92. Harley CB, Kim NW, Prowse KR, Weinrich SL, Hirsch KS, West MD, et al. Telomerase, cell immortality and cancer. Cold Spring Harbor Symp Quant Biol 1994; 59: 307-315.
93. Wright WE, Shay JW. Telomere dynamics in cancer progression and prevention: fundamental differences in human and mouse telomere biology. Nature Med 2000; 6: 849-851.
94. Rudolph KL, Chang S, Lee H-W, Blasco M, Gottlieb GJ, Greider C, et al. Longevity, stress-response and cancer in aging telomerase-deficient mice. Cell 1999; 96: 701-712.
95. Artandi SE, Chang S, Lee S-L, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406: 641-645.
96. Chang S, Multani AS, Cabrera NG, et al. Essential role of limiting telomeres in the pathogenesis of Werner syndrome. Nature Genet 2004; 36: 877-882.
97. Martin GM, Oshima J. Lessons from human progeroid syndromes. Nature 2000; 408: 263-266.
98. Hickson ID. RecQ helicases: caretakers of the genome. Nature Rev Cancer 2003; 3: 169-178.
99. Wyllie FS, Jones CJ, Skinner JW, et al. Telomerase prevents the accelerated cell ageing of Werner syndrome fibroblasts. Nature Genet 2000; 24: 16-17.
100. Schulz VP, Zakian VA, Ogburn CE, et al. Accelerated loss of telomeric repeats may not explain accelerated replicative decline of Werner syndrome cells. Hum Genet 1996; 97(6): 750-754.
101. Kipling D. Telomere structure and telomerase expression during mouse development and tumorigenesis. Eur J Cancer 1997; 33: 792-800.
102. Tyner SD, Venkatchalam A, Choi J, et al. p53 mutant mice that display early ageing associated phenotypes. Nature 2002; 415: 45-53.
103. Aplin AE, Howe A, Alahari SK, Juliano RL. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules and selections. Pharmacol Rev 1998; 50: 197-263.
104. Behrens J, Frixen U, Schipper J, Weidner M, Birchmeiser W, et al. Cell adhesion in invasion and metastasis. Semin Cell Biol 1992; 3: 169-178.
105. Takeichi M. Cadherins in cancer: implications for invasion and metastasis. Curr Opin Cell Biol 1993; 5: 806-811.
106. Perl AK, Wilgenbus P, Dahl U. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 1998; 392: 190-193.
107. Hood JD, Cheresh D. Role of integrins in cell invasion and migration. Nature Rev Cancer 2002; 2(2): 91-100.
108. 5 integrins. Nature Med 2002; 8(1): 27-34.
109. Itoh T, Tanioka M, Yoshida T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048-1051.
110. Siletti S, Kessler T, Goldberg J, Boger DL, Cheresh DA. Disruption of matrix metalloproteinase 2 binding to integrin α vβ3 by an organic molecule inhibits angiogenesis and tumour growth in vivo. PNAS 2001; 98: 119-124.
111. Bello L, Lucini V, Carrabba G, et al. Simultaneous inhibition of glioma angiogenesis, cell proliferation and invasion by a naturally-occurring fragment of human metalloproteinase-2. Cancer Res 2001; 61: 8730-8736.
112. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004; 23: 11-27.
113. Varley J. TP53, hChk2, and the Li-Fraumeni syndrome. Methods Mol Biol 2003; 222: 117-129.
114. Forster A, Pannell R, Drynan LF, et al. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer. Cancer Cell 2003; 3 449-458.
115. Gaudet F, Hodgson JG, Eden A, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300: 489-492.
116. Lei H, Oh SP, Okano M, et al. De novo DNA cytosine methyltransferase activities in mouse embryonic stem cells. Development 1996; 122: 3195-3205.
117. Li E, Bestor TH, Jeansich R. DNA methylation, genomic imprinting, and mammalian development. Cold Spring Harbor Symp Quant Biol 1993; 58: 297-305.
118. (Min/+) Dnmt1-hypomorphic mice. Cancer Res 2002; 62 1296-1299.
119. Sansom OJ, Berger J, Bishop SM, Hendrich B, Bird A, Clarke AR. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nature Genet 2003; 34: 145-147.
120. Brown SD, Hardisty RE. Mutagenesis strategies for identifying novel loci associated with disease phenotypes. Semin Cell Dev Biol 2003; 14: 19-24.
121. Beier DR. ENU mutagenesis : a work in progress. Physiol Genom 2002; 11: 111-113.
122. Hrabe de Angelis MH, Flaswinkel H, Fuchs H, et al. Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nature Genet 2000; 25: 444-447.
123. www.gsf.de/ieg/groups/enu-mouse.html 'The ENLI-mouse mutagenesis screen project', 25 September 2004.
124. Katoh M, Horiya N, Valdivia RP. Mutations induced in male germ cells after treatment of transgenic mice with ethylnitrosourea. Mutat Res 1997; 388: 229-237.
125. Sansom OJ, Reed K, Hayes AJ, et al. Loss of Apc immediately perturbs differentiation and migration in the small intestine. Genes Dev 2004; 18: 1385-1390.
126. Lyons SK. Advances in imaging mouse tumour models in vivo. J Pathol 2005; 205: 194-205.